Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.67), $0.15 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $3.99 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.